Top Doctors Closes $13 Million Round Led by Impact Partners

Top Doctors raises capital. The medical appointments and medical directory platform led by Alberto Porciani, its CEO, has closed a thirteen million dollar financing round. The round was led by the French private equity firm Impact Partners. The Institut Català de Finances (ICF), through the ICF Venture Tech II fund, has also participated in the operation, according to what Porciani told PlantaDoce.

ICF Capital is the venture capital firm of the Institut Català de Finances. Founded in 1985, ICF is the public financial institution owned by the Generalitat de Catalunya. ICF’s fourth fund is ICF Venture Tech II, focused on innovative digital technology companies with high growth potential. Investments are made primarily in equity, debt, or convertible debt, preferably in co-investment with other venture capital funds.

Drake Star Partners acted as financial advisor in this financing round. In addition, the deal allows “minority partners such as Inveready to successfully divest,” according to Porciani. The company thus culminates a goal that initially arose in 2019. The financial injection will enable Top Doctors to strengthen its presence in its main geographic areas of operation and in those with the greatest difficulty in accessing medical professionals, as well as to “continue supporting doctors in their digitalization process,” said its CEO. The company expects to exceed $16 million in revenue in 2021, up from $12 million in 2020.

Read more about Top Doctors and find the most important business headlines of the day with the Born2Invest mobile app.

Top Doctors wants to strengthen its commitment in Spain, Italy, the United Kingdom, and Mexico, among other countries

Top Doctors’ internationalization has led the company to have a global presence spanning Europe (Spain, Italy, and the United Kingdom), Latin America (Mexico, Colombia, Argentina, and Chile), and Saudi Arabia. The company has a team of 250 employees and plans to expand its workforce by a further 100 people in the next twelve months. Top Doctors offers access tools to a medical directory with more than 90,000 experts in more than 50 specialties while providing doctors with technological solutions.

Top Doctors’ software as a service (SaaS) solution offers medical specialists a set of digitization tools that include online reputation management services, medical appointment booking support, teleconsultation services and payment solutions, among others. The company also hopes to soon launch a marketplace where “doctors can sell services at more affordable prices, with more competitive prices,” says Porciani. Another noteworthy fact is that the group is expanding its facilities at 239 Muntaner Street in Barcelona, where it will now occupy two floors instead of one.

The platform offers medical pre-diagnosis, private chat, and video consultation with doctors from all medical specialties, as well as a prepayment system, a platform for exchanging medical data, TD Drive, and electronic medical prescriptions, among other services.

__

(Featured image by kamleshverm via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.